The preventive effect of halofuginone on posterior glottic stenosis in a rabbit model.
OBJECTIVE
The aim of this study was to investigate the preventive effect of halofuginone on posterior glottic stenosis (PGS) in an animal model.


METHODS
A randomized, controlled animal study.


METHODS
Sixteen male New Zealand White rabbits were used for this study. After the mucosa of posterior glottis was removed for producing PGS, the study group (eight rabbits) was given intraperitoneal halofuginone at 0.1 mg/kg/day for 4 weeks and saline was injected into peritoneum in the control group. At 4 weeks after injury, postsurgical changes of posterior glottis were evaluated by gross and histologic examination.


RESULTS
PGS was induced by the mucosal stripping of the posterior glottis. The halofuginone-treated group showed less scarring and granulation tissue formation. Also, the degree of synechia was significantly less than that of control group. Histologic analysis showed the decreased fibrosis in the halofuginone-treated group.


CONCLUSIONS
This study suggests that halofuginone can be helpful in preventing PGS after laryngeal injury.
Yoon
Yeo-Hoon
YH
Department of Otolaryngology-Head and Neck Surgery, Cancer Research Institute, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
Rha
Ki-Sang
KS
Koo
Bon Seok
BS
Park
Jae Yong
JY
Kim
Yong Min
YM
Park
Yong Ho
YH
D000818:Animals; D004195:Disease Models, Animal; D005355:Fibrosis; D005931:Glottis / Q000473:pathology; D007274:Injections, Intraperitoneal; D007829:Laryngostenosis / Q000517:prevention & control*; D008297:Male; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D052999:Quinazolinones / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D011897:Random Allocation
D010880:Piperidines; D011500:Protein Synthesis Inhibitors; D052999:Quinazolinones; C010176:halofuginone